Pivekimab Biosimilar - Research Grade

Human

IL-3RA

>1mg/ml

Human IgG1 (E356D/M358L/S442C/KDel)-Kappa

Talacotuzumab Biosimilar - Research Grade (ICH5896)

https://www.imgt.org/mAb-DB/

ICH3002

P26951

Blue ice

ICH5089 is a research-grade, unconjugated recombinant analog of pivekimab, a monoclonal antibody directed against IL-3RA (CD123), the alpha subunit of the interleukin-3 receptor. Supplied as a non-therapeutic biosimilar for research use only, it reproduces the antigen-binding specificity of the originator against human CD123 but carries no cytotoxic payload and is not the clinical drug. This makes it a useful tool for laboratories studying CD123 biology and for developing CD123-directed modalities: it can serve as a binding reference or isotype-matched comparator, a positive control in assays that detect or quantify CD123 engagement, a capture or detection reagent, and a naked-antibody backbone for in-house conjugation, ADC development, or effector-function studies. It is produced recombinantly, purified to research-grade standards, and offered as low-endotoxin material in bulk milligram-to-gram quantities to support screening, assay development, and preclinical characterization. It is intended strictly for in-vitro and preclinical research; it is not for human or veterinary use and is not a formulated therapeutic. Researchers should validate lot suitability for their specific application. IL-3RA (CD123, gene IL3RA; UniProt P26951) is a type I transmembrane glycoprotein and low-affinity, ligand-specific alpha subunit of the interleukin-3 receptor. It binds IL-3 but requires the shared common beta chain (CD131/CSF2RB) to form a high-affinity signaling complex. Ligand engagement drives heterodimerization and activation of JAK2, with downstream signaling through STAT5, PI3K, and the Ras/MAPK pathway, regulating proliferation, survival, and differentiation of hematopoietic progenitors. CD123 is expressed on hematopoietic progenitors, monocytes, basophils, and plasmacytoid dendritic cells, but is present only at low levels on normal hematopoietic stem cells. It is markedly overexpressed on the malignant blasts and putative leukemic stem cells of several hematologic malignancies, including acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm, making it a widely studied surface target for antibody- and cell-based approaches.

IL-3 receptor subunit alpha, IL-3R subunit alpha, IL-3R-alpha, Interleukin-3 receptor subunit alpha, IL3R

Detects human IL-3RA

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Q: Is the Pivekimab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this research-grade Pivekimab biosimilar suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Pivekimab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Pivekimab that binds human IL-3RA.